Anti-infectives Developed as Racemic Drugs in the 21st Century: Norm or Exception?

[Image: see text] This viewpoint outlines the case for developing new chemical entities (NCEs) as racemates in infectious diseases and where both enantiomers and racemate retain similar on- and off-target activities as well as similar PK profiles. There are not major regulatory impediments for the d...

Descripción completa

Detalles Bibliográficos
Autores principales: Cabrera, Diego González, Smith, Dennis A., Basarab, Gregory S., Duffy, James, Spangenberg, Thomas, Chibale, Kelly
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2023
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10351050/
https://www.ncbi.nlm.nih.gov/pubmed/37465315
http://dx.doi.org/10.1021/acsmedchemlett.3c00214

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10351050/
https://www.ncbi.nlm.nih.gov/pubmed/37465315
http://dx.doi.org/10.1021/acsmedchemlett.3c00214

Ejemplares similares